TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
The Promise and Potential of Economic Reforms for health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has…
Ending HIV requires sustained research. TAG’s May 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.
Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
TB testing is getting faster, cheaper, and more accessible and advocates have a critical window to act. Treatment Action Group's new factsheet breaks down WHO-recommended near point-of-care TB tests and shows how communities can use Global Fund Grant Cycle 8 to finance their rollout. With an estimated 2.7 million people going undiagnosed in 2024 alone, the tools and funding are finally aligned. Now is the time to push for change.
On World TB Day, TAG is excited to share our most recent TB vaccine materials: a new TB vax-zine, community partnership report on emerging vaccines, supply chain analysis of adjuvants that boost vaccine effectiveness, and the most recent pipeline report on TB vaccines in development.